Cell Therapy Technology Platform
CytoSeek is developing its Artificial Membrane-Binding Protein (AMBP) technology to deliver transformative cell therapies for use in cancer treatment. AMBPs, which bind to virtually all cell types, allow precision membrane engineering to deliver new functionalities. Currently, we are developing multiple AMBPs in combination with different immune cell types to treat solid tumours.
Delivering Transformative Cell Therapies
CytoSeek's mission is to deliver transformative cell therapies for cancer patients using our precision membrane engineering platform technology. The company was founded to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol. CytoSeek is now engaged in proof of principle studies, seeking to enhance cell therapies against solid tumours with our AMBP technology.
Strengthening the Fight Against Cancer
Our AMBPs are currently being developed to address limitations in cell therapies targeting solid tumours, such as efficacy, safety, and manufacturing.
AMBPs can be applied to virtually any cell type or synthetic membranes such as liposomes or lipid nanoparticles (LNPs), and their modular design allows us to Arm cells with stimulating proteins, Aim cells and vectors to specific cell types, and Amplify the number of cells through proliferation.
We are seeking partnerships to co-develop our technology with cell therapy developers. Please get in touch if you'd like further information.
